Therapeutics Articles
This trial suggests that plasma exchange with albumin replacement could slow cognitive and functional decline in Alzheimer’s disease, although further studies are warranted.
The investigators concluded lower, more frequent dosing does not further improve the efficacy of IVIG in stable IVIG-dependent CIDP patients, or result in fewer side effects.
Titrating the IgG trough level up to 960 mg/dL progressively reduces the infection rate in PI patients, but there is less incremental benefit above this trough level.
More than two years after receiving Spark Therapeutics’ investigational adeno-associated virus (AAV)-mediated gene therapy (SPK-8011), five adult subjects with hemophilia A exhibited stable factor VIII (FVIII) expression, with no evidence of FVIII inhibitors or a cellular immune response.
Investigators conducted a retrospective review of 38 cases treated at Taipei Veterans General Hospital between January 2007 and December 2018 to determine whether more aggressive albumin supplementation can benefit major burn patients with persistent hypoalbuminemia.
Researchers have found combining immune tolerance induction (ITI) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A.
The U.S. Food and Drug Administration (FDA) has approved WILATE for treatment of adults and adolescents with hemophilia A for routine prophylaxis.
The Centers for Medicare and Medicaid Services (CMS) finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).
A study out of the University of Texas Southwestern Medical Center found a 96 percent response rate to treatment with therapeutic plasma exchange (PLEX) in a series of 58 consecutive myasthenia gravis (MG) patients, with no significant difference in response between those with or without autoantibodies.
FDA approved Esperoct (antihemophilic factor[recombinant], glycopegylatedexei), an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A.
FDA has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive
therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura.
